Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Islets of Langerhans Clear all
Not listed No phase listed Observational

Patterns and Natural History of Insulin Secretion in Islet Cell Transplant Recipients and Controls

NCT00018122
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 4:23 PM EDT
Not listed Phase 1Phase 2 Interventional

Islet Transplant in Patients With Type I Diabetes

NCT03698396
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic Islet Cell Transplantation
Biological
Lead sponsor
Kenneth Brayman, MD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 25, 2026, 4:23 PM EDT
Completed Not applicable Interventional Results available

Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas

NCT01762059
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Bi-homonal Bionic Pancreas, Usual care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 25, 2026, 4:23 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Islet After Kidney Transplant for Type 1 Diabetes

NCT00784966
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
etanercept
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Sep 25, 2026, 4:23 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes

NCT00285233
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Allogeneic islets of Langerhans transplant
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 25, 2026, 4:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Feasibility of a Mobile Electronic Mindfulness Therapy Service for Chronic Pancreatitis

NCT02224898
View directory record Official record
Conditions
Pancreatitis, Chronic
Interventions
Mobile Mindfulness Therapy
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 25, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

NCT00113360
View directory record Official record
Conditions
Neuroendocrine Carcinoma, Islet Cell Carcinoma
Interventions
RAD001, Octreotide Depot
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 25, 2026, 4:23 PM EDT
Completed Phase 1Phase 2 Interventional

Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation

NCT00286624
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Allogeneic Islets of Langerhans, Everolimus, anti-thymocyte globulin, Cyclosporine
Biological · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2008 · Synced Sep 25, 2026, 4:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

NCT06575426
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Islet Cell Transplantation, Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D), Severe Hypoglycemia, Xenotransplantation, Hypoglycemic Episode, Islet Transplantation in Diabetes Mellitus Type 1, Glucose Metabolism Disorders (Including Diabetes Mellitus), Immune System Diseases, Autoimmune Diseases, Metabolic Disease
Interventions
OPF-310
Combination Product
Lead sponsor
Otsuka Pharmaceutical Factory, Inc.
Industry
Eligibility
35 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 25, 2026, 4:23 PM EDT
Recruiting Phase 2 Interventional

Islet Transplantation in Type 1 Diabetic Kidney Allograft

NCT01241864
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
Biological · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 68 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 25, 2026, 4:23 PM EDT
Completed Phase 1Phase 2 Interventional

Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus

NCT00501709
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Belatacept and Raptiva
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 25, 2026, 4:23 PM EDT
Terminated Phase 1Phase 2 Interventional

Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus

NCT00579371
View directory record Official record
Conditions
Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1
Interventions
Islets of Langerhans
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 25, 2026, 4:23 PM EDT
Completed Phase 1Phase 2 Interventional

Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes

NCT03977662
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Co-transplantation of PTG with pancreatic islets
Combination Product
Lead sponsor
Peter Stock
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 25, 2026, 4:23 PM EDT
Terminated Phase 2 Interventional

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

NCT00466856
View directory record Official record
Conditions
Head and Neck Cancer, Islet Cell Tumor, Metastatic Cancer, Pheochromocytoma
Interventions
octreotide acetate, yttrium Y 90 resin microspheres
Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Sep 25, 2026, 4:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients

NCT00888628
View directory record Official record
Conditions
Diabetes Mellitus, Type I
Interventions
Purified Pancreatic Islets, Etanercept
Biological · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 25, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors

NCT00510068
View directory record Official record
Conditions
Advanced Neuroendocrine Tumors of Pancreatic Origin
Interventions
Everolimus, Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
24
States / cities
Mobile, Alabama • Anaheim, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 25, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

LEA29Y (Belatacept) Emory Edmonton Protocol

NCT00468403
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Sep 25, 2026, 4:23 PM EDT
Completed Phase 1 Interventional

Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

NCT00005860
View directory record Official record
Conditions
Cancer
Interventions
floxuridine, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Sep 25, 2026, 4:23 PM EDT
No Longer Available No phase listed Expanded access

Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

NCT01309022
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Sirolimus, Tacrolimus, Mycophenolate mofetil, Mycophenolic acid
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 25, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

EPO906 in Carcinoid and Other Neuroendocrine Tumors

NCT00050349
View directory record Official record
Conditions
Carcinoid, Neuroendocrine Tumors
Interventions
EPO906 epothilone B
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
5
States / cities
Chicago, Illinois • Iowa City, Iowa • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 25, 2026, 4:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

NCT01967888
View directory record Official record
Conditions
Pancreatectomy for Chronic Pancreatitis
Interventions
Reparixin, Placebo
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 25, 2026, 4:23 PM EDT
Recruiting No phase listed Observational

The T1D Exchange Registry

NCT04629586
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes, Type 1 Diabetes, Diabetes Mellitus
Interventions
No intervention
Other
Lead sponsor
T1D Exchange, United States
Other
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2023 · Synced Sep 25, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas

NCT00001165
View directory record Official record
Conditions
Islet Cell Adenoma, Neoplasm Metastasis, Zollinger Ellison Syndrome
Interventions
combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1978 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 4:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intra-Portal Alone Versus Intra- and Extra-Portal Transplantation of Pancreatic Islets After Total Pancreatectomy for Chronic Pancreatitis

NCT03779139
View directory record Official record
Conditions
Chronic Pancreatitis, Diabetes Mellitus, Islet Cell Transplantation
Interventions
Intrahepatic islets and islets in the omental pouch, Intrahepatic islets alone, Normal Volunteers
Procedure · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 68 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 25, 2026, 4:23 PM EDT